File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome

TitleObestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
Authors
Issue Date2020
PublisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html
Citation
Scientific Reports, 2020, v. 10, p. article no. 5495 How to Cite?
AbstractMetabolic syndrome (MetS) is a multi-factorial disorder including central obesity (CO), insulin resistance, hyperglycemia, dyslipidemia and hypertension which increases the risk of diabetes mellitus and cardiovascular diseases. CO is considered as an essential component of MetS according to International Diabetes Federation (IDF), which may further modulate distinct signalling pathways compared with the other four MetS risk factors. Given that ghrelin signalling and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis regulates energy balance and metabolic homeostasis, this study examined the changes in various ghrelin products and circulating hormones in response to the interaction between CO and other MetS components including blood pressure, fasting blood glucose, triglycerides, and high-density lipoprotein cholesterol in 133 Hong Kong Chinese adults. Circulating obestatin and GH were increased and reduced, respectively, by either CO or the other 4-risk factor cluster. These changes were further augmented by the presence of all MetS risk factors. However, changes of ghrelin levels were not mediated by CO but the other MetS risk factors. Our findings suggest that CO does not predict all the dysregulation of signalling pathways in individuals with MetS. Although CO and other MetS may share common signalling targets (i.e., obestatin and GH), CO does not contribute to the perturbation of ghrelin signalling.
Persistent Identifierhttp://hdl.handle.net/10722/281845
ISSN
2020 Impact Factor: 4.379
2020 SCImago Journal Rankings: 1.240
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYU, AP-
dc.contributor.authorUgwu, FN-
dc.contributor.authorTam, BT-
dc.contributor.authorLee, PH-
dc.contributor.authorMa, V-
dc.contributor.authorPang, S-
dc.contributor.authorChow, AS-
dc.contributor.authorCheng, KK-
dc.contributor.authorLai, CW-
dc.contributor.authorWong, CS-
dc.contributor.authorSiu, PM-
dc.date.accessioned2020-04-03T07:22:37Z-
dc.date.available2020-04-03T07:22:37Z-
dc.date.issued2020-
dc.identifier.citationScientific Reports, 2020, v. 10, p. article no. 5495-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/10722/281845-
dc.description.abstractMetabolic syndrome (MetS) is a multi-factorial disorder including central obesity (CO), insulin resistance, hyperglycemia, dyslipidemia and hypertension which increases the risk of diabetes mellitus and cardiovascular diseases. CO is considered as an essential component of MetS according to International Diabetes Federation (IDF), which may further modulate distinct signalling pathways compared with the other four MetS risk factors. Given that ghrelin signalling and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis regulates energy balance and metabolic homeostasis, this study examined the changes in various ghrelin products and circulating hormones in response to the interaction between CO and other MetS components including blood pressure, fasting blood glucose, triglycerides, and high-density lipoprotein cholesterol in 133 Hong Kong Chinese adults. Circulating obestatin and GH were increased and reduced, respectively, by either CO or the other 4-risk factor cluster. These changes were further augmented by the presence of all MetS risk factors. However, changes of ghrelin levels were not mediated by CO but the other MetS risk factors. Our findings suggest that CO does not predict all the dysregulation of signalling pathways in individuals with MetS. Although CO and other MetS may share common signalling targets (i.e., obestatin and GH), CO does not contribute to the perturbation of ghrelin signalling.-
dc.languageeng-
dc.publisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html-
dc.relation.ispartofScientific Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleObestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome-
dc.typeArticle-
dc.identifier.emailSiu, PM: pmsiu@hku.hk-
dc.identifier.authoritySiu, PM=rp02292-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41598-020-62271-w-
dc.identifier.pmid32218464-
dc.identifier.pmcidPMC7099091-
dc.identifier.scopuseid_2-s2.0-85082421522-
dc.identifier.hkuros309681-
dc.identifier.volume10-
dc.identifier.spagearticle no. 5495-
dc.identifier.epagearticle no. 5495-
dc.identifier.isiWOS:000563333800001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2045-2322-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats